scholarly journals Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

2021 ◽  
Author(s):  
Se Yong Jung ◽  
Min Seo Kim ◽  
Han Li ◽  
Keum Hwa Lee ◽  
Ai Koyanagi ◽  
...  
Keyword(s):  
World Health Organization ◽  
Cardiovascular Events ◽  
World Health ◽  
Safety Outcomes ◽  
Pharmacovigilance Database ◽  
Health Organization

scholarly journals Associations between osteoporosis and drug exposure: a post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)

Bone ◽  
2021 ◽  
pp. 116137
Author(s):  
Benjamin Batteux ◽  
Youssef Bennis ◽  
Sandra Bodeau ◽  
Kamel Masmoudi ◽  
Anne-Sophie Hurtel-Lemaire ◽  
...  
Keyword(s):  
World Health Organization ◽  
Drug Exposure ◽  
World Health ◽  
The World ◽  
Pharmacovigilance Database ◽  
Post Marketing ◽  
Health Organization

Impact of the “French Levothyrox crisis” on signal detection in the World Health Organization pharmacovigilance database

2018 ◽  
Vol 27 (12) ◽  
pp. 1427-1428 ◽  
Author(s):  
Charles Khouri ◽  
Bruno Revol ◽  
Marion Lepelley ◽  
Michel Mallaret ◽  
Jean-Luc Cracowski
Keyword(s):  
Signal Detection ◽  
World Health Organization ◽  
World Health ◽  
The World ◽  
Pharmacovigilance Database ◽  
Health Organization

scholarly journals Long Covid: A Review on Cardiovascular Disease (CVD) in Post-Acute Sequalae of SARS-CoV-2 Infection (PASC)

2021 ◽  
Vol 12 (3) ◽  
pp. 3989-3995
Keyword(s):  
Cardiovascular Disease ◽  
Chest Pain ◽  
World Health Organization ◽  
Joint Pain ◽  
Cardiovascular Events ◽  
World Health ◽  
Number Of Patients ◽  
The World ◽  
Surface Receptor ◽  
Health Organization

Coronavirus disease 2019 (COVID-19) caused by the virus SARS-CoV-2 was declared a pandemic by the World Health Organization (WHO) in March 2020. The clinical spectrum of COVID-19 can range from asymptomatic to severe symptoms and even death. Recent studies show that a growing number of patients with COVID-19 will experience prolonged symptoms (Post-Acute Sequalae of SARS-CoV-2), which now days known as “Long Covid”. A team of researchers from Italy reported that nearly 9 in 10 patients discharged were still experiencing at least one symptom 60 days after infection. Symptoms reported are fatigue, dyspnea, joint pain, chest pain, and other uncommon symptoms. Through ACE2 surface receptor, SARS-CoV-2 has been linked to cardiovascular events. As PASC symptoms vary widely, cardiovascular sequelae need to be considered through lifetime management. Therefore, this review aims to summarize an update of the long covid effect on Cardiovascular Disease (CVD), the impacts, and Post-Acute Sequalae of SARS-CoV-2 Infection (PASC) management.

scholarly journals Tramadol-induced hiccups: a case–noncase study in the European pharmacovigilance database

2021 ◽  
Vol 12 ◽  
pp. 204209862110212
Author(s):  
Montserrat García ◽  
Unax Lertxundi ◽  
Carmelo Aguirre
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
World Health Organization ◽  
Case Reports ◽  
Opioid Analgesic ◽  
World Health ◽  
Plain Language ◽  
The World ◽  
Pharmacovigilance Database ◽  
Health Organization

Background: Hiccups are usually benign and self-limiting, but can sometimes be persistent. If left untreated, they can provoke severe discomfort, and even death. Hiccups can be idiopathic, organic, psychogenic, and caused by drugs. Although some case reports have suggested a possible association between tramadol and hiccups, to our knowledge, no study has analyzed this possible relationship. The aim of this study was to analyze whether a disproportionate number of cases of hiccups are reported for tramadol in the EudraVigilance database. Methods: A case–noncase study was conducted to assess the association between hiccups and tramadol, calculating reporting odds ratios (RORs) from 1 January 1995 to 11 September 2020. Cases were selected using the preferred term ‘Hiccups’. The noncases used as controls were all other adverse drug reaction reports recorded in EudraVigilance during the same period. Exposure was defined as exposure to tramadol among cases and noncases. To reduce the risk of confounding by indication, the RORs for tramadol compared with other opioids were obtained. Additionally, we performed a confirmatory analysis in the World Health Organization pharmacovigilance database, VigiBase®. Results: There were 3089 cases of hiccups in the 7,213,623 reports. Tramadol was involved in 50 cases. The ROR for tramadol exposure was 3.35 [95% confidence interval (CI) 2.53–4.43]. This association persisted when comparing tramadol with other opioids; ROR: 2.13 (95% CI 1.52–2.99). Disproportionality was also observed in VigiBase®: ROR 1.69 (95% CI 1.47–1.93). Conclusion: Our study confirms, for the first time, a possible signal for a tramadol–hiccups association. Nevertheless, observational analytical studies are needed to confirm these results Plain Language Summary Evaluation of the relationship between the tramadol and the risk of hiccups Introduction: Hiccups are sudden involuntary contractions of the diaphragm. This involuntary contraction causes the vocal cords to close very briefly, which produces the characteristic sound of a hiccup. Hiccups are usually benign and self-limiting, but can sometimes be persistent. If left untreated, they can provoke severe discomfort, depression, disability, and in the most extreme cases, even death. Drugs are a rare cause of hiccups. Methods: This study investigated the possible association between tramadol and hiccups (an unmentioned adverse drug reaction in the Summary of Product Characteristics) in the European pharmacovigilance database (EudraVigilance) and a confirming analysis in the World Health Organization pharmacovigilance database (VigiBase). Results: Our analysis shows that hiccups is relatively more frequently reported in association with tramadol than with other medicinal products, with EudraVigilance and VigiBase confirming this association. Conclusion: Tramadol is an opioid analgesic indicated, alone or in combination with dexketoprofen or paracetamol for pain with various causes, so healthcare professionals and patients should be aware of this possible association.

Sign in / Sign up

Export Citation Format

Share Document